|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.220 USD | -1.50% |
|
+3.14% | -18.14% |
| Apr. 09 | Vanda Asks FDA to Withdraw Proposal Extending Drug Review Timelines | MT |
| Apr. 08 | Vanda Pharmaceuticals Starts Study of Nereus to Address GLP-1 Side Effects | MT |
Company Valuation: Vanda Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 874.1 | 418.2 | 242.8 | 279.3 | 521.2 | 426.8 | - | - |
| Change | - | -52.16% | -41.95% | 15.04% | 86.62% | -18.12% | - | - |
| Enterprise Value (EV) 1 | 874.1 | 418.2 | 242.8 | 279.3 | 521.2 | 253.5 | 265.7 | 426.8 |
| Change | - | -52.16% | -41.95% | 15.04% | 86.62% | -51.36% | 4.79% | 60.62% |
| P/E ratio | 27.1x | 67.2x | 106x | -14.5x | -2.36x | -3.23x | -9.12x | 167x |
| PBR | - | - | - | - | - | 1.92x | 2.3x | - |
| PEG | - | -0.8x | -1.7x | 0x | -0x | 0.1x | 0.1x | -2x |
| Capitalization / Revenue | 3.25x | 1.64x | 1.26x | 1.41x | 2.41x | 1.66x | 1.21x | 0.94x |
| EV / Revenue | 3.25x | 1.64x | 1.26x | 1.41x | 2.41x | 0.99x | 0.75x | 0.94x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 20.7x | 66.1x | -17.4x | -6.87x | -3.45x | -1.58x | -3.73x | -291x |
| EV / FCF | - | - | - | -13.6x | -4.72x | -1.9x | -5.03x | 56.9x |
| FCF Yield | - | - | - | -7.33% | -21.2% | -52.7% | -19.9% | 1.76% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.58 | 0.11 | 0.04 | -0.33 | -3.74 | -2.236 | -0.792 | 0.0433 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 268.7 | 254.4 | 192.6 | 198.8 | 216.1 | 257.1 | 353.3 | 453.8 |
| EBITDA | 45.01 | - | - | - | - | - | - | - |
| EBIT 1 | 42.16 | 6.329 | -13.95 | -40.66 | -151.2 | -160.7 | -71.22 | -1.467 |
| Net income 1 | 33.15 | 6.275 | 2.509 | -18.9 | -220.5 | -133.5 | -55.5 | -1 |
| Net Debt 1 | - | - | - | - | - | -173.2 | -161.1 | - |
| Reference price 2 | 15.690 | 7.390 | 4.220 | 4.790 | 8.820 | 7.220 | 7.220 | 7.220 |
| Nbr of stocks (in thousands) | 55,712 | 56,590 | 57,532 | 58,308 | 59,097 | 59,108 | - | - |
| Announcement Date | 2/23/22 | 2/8/23 | 2/7/24 | 2/13/25 | 2/11/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.23x | 0.99x | - | - | 427M | |
| 27.95x | 7.4x | 22.05x | 0.05% | 49.79B | |
| 18.25x | 5.44x | 12.35x | 1.62% | 46.97B | |
| -59.72x | 19.31x | -65.3x | -.--% | 33.42B | |
| -18.17x | 4.01x | -7.52x | -.--% | 24.15B | |
| 28.54x | 5.58x | 15.51x | -.--% | 18.97B | |
| 23.1x | 4.04x | 12.35x | -.--% | 17.25B | |
| -393.24x | 32.84x | 1807.92x | -.--% | 16.25B | |
| -15.77x | 1757.99x | -21.98x | -.--% | 15.25B | |
| -205.97x | 50.1x | -198.99x | -.--% | 14.68B | |
| Average | -59.83x | 188.77x | 175.15x | 0.19% | 23.72B | |
| Weighted average by Cap. | -37.54x | 124.91x | 109.63x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- VNDA Stock
- Valuation Vanda Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
